Efficient entry inhibition of human and nonhuman primate immunodeficiency virus by cell surface-expressed gp41-derived peptides.
about
Survival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infectionComputational prediction of anti HIV-1 peptides and in vitro evaluation of anti HIV-1 activity of HIV-1 P24-derived peptides.Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates.Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAARTFunctional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody.A quantitative comparison of anti-HIV gene therapy delivered to hematopoietic stem cells versus CD4+ T cells.Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino TerminusA rationally engineered anti-HIV peptide fusion inhibitor with greatly reduced immunogenicityMultilineage polyclonal engraftment of Cal-1 gene-modified cells and in vivo selection after SHIV infection in a nonhuman primate model of AIDSPhase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells.CCR5 as a natural and modulated target for inhibition of HIV.Glycosylphosphatidylinositol-Anchored Anti-HIV scFv Efficiently Protects CD4 T Cells from HIV-1 Infection and Deletion in hu-PBL Mice.Practical considerations in gene therapy for HIV cure.Stem cell gene therapy for HIV: strategies to inhibit viral entry and replication.Stem cell-based therapies for HIV/AIDS.Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor.Phase I/II Clinical Trials Using Gene-Modified Adult Hematopoietic Stem Cells for HIV: Lessons Learnt.Modeling Anti-HIV-1 HSPC-Based Gene Therapy in Humanized Mice Previously Infected with HIV-1.
P2860
Q28749594-6434531C-E1EF-4DD2-950F-6DB41715DD50Q30368769-D84772B5-439F-4408-B8D0-9946990456A3Q33968014-DBC429D9-9F95-480D-A489-7937027B0F34Q34647798-73D4B5C3-9331-4385-AACA-35A6CBD76CF1Q35168642-C5B991D4-A439-4146-9B8E-F0291203E557Q35191116-0A3022C8-0D07-48C6-AA0C-817FEBC47039Q36195192-261B770C-8EE3-40A4-9B19-156E0047575BQ36558535-A26388E9-EA09-4054-998C-EA6C7E78B5BFQ36613666-F61C55FA-6A15-425A-9365-108834DB8BC0Q37401812-D5F46C96-3AE4-4F2E-988D-89DDC482F76AQ37566693-7AFE231F-1011-4AC9-8012-4EBFAD4817FFQ37593222-6F3D3A61-54E5-4477-8898-C66076582A32Q38180645-3F8CF96E-CDF1-4DCD-84D1-D9D5E0D17ABFQ38314119-E61F5CF0-A625-4703-B2E3-25EA61D13821Q38827119-6C2A6DEF-C280-459D-AB87-20C966364EFAQ39600778-59895F98-AB7C-4DC9-A72D-7B618D13CBDBQ42760569-65464CDA-E6CA-402D-AD77-C4ADA0913D14Q49309806-7D6A0DC2-C993-43F3-97F2-D072116946FA
P2860
Efficient entry inhibition of human and nonhuman primate immunodeficiency virus by cell surface-expressed gp41-derived peptides.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Efficient entry inhibition of ...... pressed gp41-derived peptides.
@ast
Efficient entry inhibition of ...... pressed gp41-derived peptides.
@en
type
label
Efficient entry inhibition of ...... pressed gp41-derived peptides.
@ast
Efficient entry inhibition of ...... pressed gp41-derived peptides.
@en
prefLabel
Efficient entry inhibition of ...... pressed gp41-derived peptides.
@ast
Efficient entry inhibition of ...... pressed gp41-derived peptides.
@en
P2093
P2860
P356
P1433
P1476
Efficient entry inhibition of ...... xpressed gp41-derived peptides
@en
P2093
D von Laer
F G Hermann
F Villinger
R P Johnson
P2860
P2888
P304
P356
10.1038/GT.2008.73
P577
2008-05-01T00:00:00Z